Companies
Companies
Labcorp Investor Day reaffirms FY2026 guidance and long-term outlook through 2029
The laboratory-services company kept its full-year forecast intact and set out expectations for 5%–8% compound annual revenue growth and 8.5%–11.5% adjusted earnings-per-share growth through 2029.
TickerGrove Newsroom · Published · Event · Labcorp Holdings Inc. Form 8-K — Investor Day / Regulation FD
Sources
Verified facts from Labcorp Holdings Inc. Form 8-K AccNo 0000920148-26-000201 (Items 7.01/9.01), Exhibit 99.1 Investor Day press release, and Exhibit 99.2 Investor Day presentation. Filed September 10, 2026; CIK 0000920148; ticker LH (NYSE). Company hosted 2026 Investor Day beginning 9 a.m. ET on September 10, reaffirmed full-year 2026 guidance last updated July 30, 2026 (Enterprise revenue $14,710M–$14,827M; Diagnostics $11,450M–$11,532M; Biopharma $3,269M–$3,300M; Adjusted EPS $18.10–$18.55; Free Cash Flow $1,240M–$1,360M), and outlined long-term outlook through 2029 (revenue CAGR 5%–8%; adjusted operating margin expansion 75–150 bps by end-2029; adjusted EPS CAGR 8.5%–11.5%; free cash flow CAGR in line with adjusted earnings). Read as Investor Day disclosure / guidance reaffirm + long-term outlook — not as a guidance raise/cut, earnings print, or closed M&A. No share-price reaction or competitor metrics are stated here.
Facts are as of Labcorp's September 10, 2026 Investor Day (Form 8-K / Exhibits 99.1 and 99.2 filed September 10, 2026). Read as Investor Day disclosure with FY2026 guidance reaffirm (last updated July 30, 2026) and company-attributed long-term outlook through 2029 — not as a guidance raise/cut or closed transaction.
Visual brief
Verified figures
Sources & evidenceUSD millions
$14,710M–$14,827M
Labcorp Enterprise revenue guidance (FY2026; reaffirmed)
FY2026 guidance reaffirmed at Investor Day September 10, 2026; last updated July 30, 2026; AccNo 0000920148-26-000201
Labcorp Holdings Inc. via SEC EDGARLabcorp Exhibit 99.1 — September 10, 2026 Investor Day press releaseSEC Exhibit 99.1 press release · 09-10-2026USD per share
$18.10–$18.55
Adjusted EPS guidance (FY2026; reaffirmed)
FY2026 guidance reaffirmed at Investor Day September 10, 2026; AccNo 0000920148-26-000201
Labcorp Holdings Inc. via SEC EDGARLabcorp Exhibit 99.1 — September 10, 2026 Investor Day press releaseSEC Exhibit 99.1 press release · 09-10-2026CAGR
5%–8% revenue CAGR
Long-term compound annual revenue growth outlook through 2029
Long-term outlook through 2029; Investor Day September 10, 2026; AccNo 0000920148-26-000201
Labcorp Holdings Inc. via SEC EDGARLabcorp Exhibit 99.1 — September 10, 2026 Investor Day press releaseSEC Exhibit 99.1 press release · 09-10-2026
Labcorp (NYSE: LH) hosted its 2026 Investor Day on September 10 and reaffirmed full-year 2026 guidance last updated July 30, 2026, while outlining a long-term outlook through 2029 that targets compound annual revenue growth of 5% to 8% and compound annual adjusted EPS growth of 8.5% to 11.5%.
Investor Day and FY2026 guidance reaffirm
Labcorp Holdings Inc. hosted its 2026 Investor Day beginning at 9 a.m. ET on September 10, 2026, and reaffirmed full-year 2026 guidance last updated July 30, 2026. Guidance assumes foreign exchange rates as of June 30, 2026, and enterprise guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.
Enterprise, Diagnostics, and Biopharma revenue ranges
Reaffirmed FY2026 ranges include Labcorp Enterprise revenue of $14,710M–$14,827M (growth 5.4% to 6.3% versus 2025 Enterprise revenue of $13,952M), Diagnostics Laboratories revenue of $11,450M to $11,532M, and Biopharma Laboratory Services revenue of $3,269M to $3,300M.
Adjusted EPS and free cash flow guidance
Labcorp also reaffirmed Adjusted EPS of $18.10 to $18.55 and Free Cash Flow of $1,240M to $1,360M for full-year 2026.
Long-term outlook through 2029
Looking beyond 2026, Labcorp outlined a long-term outlook through 2029: compound annual revenue growth between 5% and 8%; adjusted operating margin expansion between 75 and 150 basis points by the end of 2029; compound annual adjusted EPS growth of 8.5% to 11.5%; and compound annual free cash flow growth in line with adjusted earnings growth. Those bands are company outlook, not guaranteed outcomes.
Strategic priorities and webcast
Strategic priorities highlighted at Investor Day included specialty testing leadership, partnerships with health systems and pharmaceutical companies, personalized health solutions, and advanced technology including AI and robotics. A webcast ran via Labcorp Investor Relations beginning 9 a.m. ET, with replay and materials available after the event.
Quarterly earnings detail and share-price reaction remain outside this Investor Day disclosure
The Form 8-K and Exhibit 99.1 establish that Labcorp hosted Investor Day, reaffirmed July 30 FY2026 guidance, and outlined long-term outlook through 2029; they do not report a guidance raise or cut, invent share-price reaction, or present the long-term CAGR bands as guaranteed outcomes.
Document trail
Sources & evidence
Primary documents used for this piece.
Labcorp Holdings Inc. via SEC EDGAR
Labcorp Exhibit 99.1 — September 10, 2026 Investor Day press release
SEC Exhibit 99.1 press release · 2026-09-10
U.S. Securities and Exchange Commission (EDGAR)
Labcorp Form 8-K filing index — AccNo 0000920148-26-000201
SEC Form 8-K index · 2026-09-10
Labcorp Holdings Inc. via SEC EDGAR
Labcorp Exhibit 99.2 — 2026 Investor Day presentation
SEC Exhibit 99.2 presentation · 2026-09-10
Corrections
We do not silently rewrite a published line. Material corrections receive a visible correction note, and we preserve the article’s update history.
Discuss this story. Join the TickerGrove community to talk companies, earnings, and markets, or request future coverage.